ImmunityBio, Inc.
NASDAQ:IBRX
3.58 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.622 | 0.24 | 0.934 | 0.605 | 2.202 | 0.047 | 0.045 | 0.044 | 0.236 | 0.641 |
| Cost of Revenue
| 18.512 | 24.192 | 0 | 9.147 | 9.012 | -3.11 | 0 | 0 | 0 | 0 |
| Gross Profit
| -17.89 | -23.952 | 0.934 | -8.542 | -6.81 | 3.157 | 0.045 | 0.044 | 0.236 | 0.641 |
| Gross Profit Ratio
| -28.762 | -99.8 | 1 | -14.119 | -3.093 | 67.17 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 213.854 | 248.149 | 195.958 | 139.507 | 111.997 | 53.418 | 39.778 | 26.546 | 11.434 | 1.595 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 28.394 | 57.121 | 95.391 | 227.678 | 4.326 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 7.069 | -3.3 | -1 | -1.472 | 0 |
| SG&A
| 129.62 | 102.708 | 135.256 | 71.318 | 46.456 | 35.463 | 53.821 | 94.391 | 226.206 | 4.326 |
| Other Expenses
| -38.426 | -0.736 | 0.193 | 1.486 | -0.534 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 343.474 | 350.857 | 331.214 | 210.825 | 158.453 | 88.881 | 93.599 | 120.937 | 237.64 | 5.921 |
| Operating Income
| -361.364 | -351.298 | -330.28 | -220.88 | -156.251 | -98.389 | -99.12 | -124.5 | -238.876 | -6.212 |
| Operating Income Ratio
| -580.971 | -1,463.742 | -353.619 | -365.091 | -70.959 | -2,093.383 | -2,202.667 | -2,829.545 | -1,012.186 | -9.691 |
| Total Other Income Expenses Net
| -222.528 | -65.988 | -19.559 | -5.153 | -4.012 | 1.66 | 2.204 | 3.119 | 1.699 | 0 |
| Income Before Tax
| -583.892 | -417.286 | -349.839 | -226.033 | -160.263 | -96.729 | -96.916 | -121.381 | -237.177 | -6.212 |
| Income Before Tax Ratio
| -938.733 | -1,738.692 | -374.56 | -373.608 | -72.781 | -2,058.064 | -2,153.689 | -2,758.659 | -1,004.987 | -9.691 |
| Income Tax Expense
| -0.04 | 0.034 | 0.009 | -1.846 | -0.105 | -0.503 | -0.493 | -0.572 | -0.301 | 0.001 |
| Net Income
| -583.196 | -417.32 | -349.848 | -224.187 | -160.158 | -96.226 | -96.423 | -120.809 | -236.876 | -6.213 |
| Net Income Ratio
| -937.614 | -1,738.833 | -374.57 | -370.557 | -72.733 | -2,047.362 | -2,142.733 | -2,745.659 | -1,003.712 | -9.693 |
| EPS
| -1.15 | -1.04 | -0.9 | -0.59 | -0.42 | -1.22 | -1.2 | -1.47 | -3.31 | -0.02 |
| EPS Diluted
| -1.15 | -1.04 | -0.9 | -0.59 | -0.42 | -1.22 | -1.2 | -1.47 | -3.31 | -0.02 |
| EBITDA
| -342.852 | -343.978 | -316.304 | -195.128 | -139.976 | -88.834 | -93.554 | -120.893 | -237.404 | -6.084 |
| EBITDA Ratio
| -551.209 | -1,433.242 | -338.655 | -322.526 | -63.568 | -1,890.085 | -2,078.978 | -2,747.568 | -1,005.949 | -9.491 |